REVERSOL Drug Patent Profile
✉ Email this page to a colleague
When do Reversol patents expire, and what generic alternatives are available?
Reversol is a drug marketed by Organon Usa Inc and is included in one NDA.
The generic ingredient in REVERSOL is edrophonium chloride. There are three drug master file entries for this compound. Additional details are available on the edrophonium chloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REVERSOL?
- What are the global sales for REVERSOL?
- What is Average Wholesale Price for REVERSOL?
Summary for REVERSOL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| DailyMed Link: | REVERSOL at DailyMed |
US Patents and Regulatory Information for REVERSOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon Usa Inc | REVERSOL | edrophonium chloride | INJECTABLE;INJECTION | 089624-001 | May 13, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
